The additional value of the CRP test in patients in whom the primary care physician excluded pulmonary embolism

Eur J Gen Pract. 2013 Sep;19(3):143-9. doi: 10.3109/13814788.2013.780019. Epub 2013 Apr 12.

Abstract

Background: After excluding pulmonary embolism (PE) with an unlikely Wells-decision rule and a negative D-dimer test, the general practitioner still has to differentiate between clinically relevant and clinically non-relevant diseases accounting for the presented symptoms. A negative D-dimer test makes clinically relevant disease less likely. The C-reactive protein (CRP) test could be of additional value to make this differentiation.

Objectives: To assess whether an unlikely Wells-decision rule in combination with a negative point of care D-dimer test not only can safely exclude PE but also, in combination with a negative CRP-test, any other clinically relevant disease.

Methods: We used data of a prospective study including 598 primary care patients suspected of pulmonary embolism. We included all patients, referred to secondary care for reference testing, with an unlikely Wells-decision rule and a negative point of care D-dimer test. We included 191 patients and imputed the CRP-test results in 60 patients. Alternative diagnoses were divided in clinically relevant diseases and clinically non-relevant diseases. A ROC-curve was constructed to determine the optimal CRP-cut-off.

Results: The optimal CRP cut-off value appeared to be 10 mg/l. A total of 116 patients had a CRP < 10 mg/l of whom 12 patients (10%) had a clinically relevant disease. Two patients (2%) needed hospital admission. A total of 75 patients had a CRP ≥ 10 mg/l of whom 32 patients (43%) had a clinically relevant disease. Fifteen patients (20%) were admitted to hospital.

Conclusion: The CRP-test is enhancing diagnostic decision making in patients in whom the general practitioner excluded PE.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • C-Reactive Protein / analysis*
  • Cohort Studies
  • Decision Making
  • Diagnosis, Differential
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis*
  • General Practice / methods
  • Humans
  • Male
  • Middle Aged
  • Primary Health Care / methods*
  • Prospective Studies
  • Pulmonary Embolism / diagnosis*
  • ROC Curve
  • Young Adult

Substances

  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D
  • C-Reactive Protein